Chemical Property of Fesoterodine
Chemical Property:
- Appearance/Colour:White solid
- Melting Point:72-78 °C
- Boiling Point:518.9 °C at 760 mmHg
- Flash Point:267.6 °C
- PSA：124.37000
- LogP:5.09290
- Storage Temp.:Hygroscopic, Store under Inert atmosphere -20°C Freezer
- Solubility.:DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly)
- XLogP3:5.5
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:4
- Rotatable Bond Count:11
- Exact Mass:411.27734404
- Heavy Atom Count:30
- Complexity:491
- Purity/Quality:
-
99%, *data from raw suppliers
(R)-FesoterodineFumarate *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Drug Classes:Anticholinergic Agents
- Canonical SMILES:CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2
- Isomeric SMILES:CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2
- Recent ClinicalTrials:Fall Prevention in Older Adults With OAB
- Recent EU Clinical Trials:A 24-WEEK RANDOMIZED, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY)
- Recent NIPH Clinical Trials:The efficacy of Fesoterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder
-
Description
Fesoterodine fumarate is a new drug for the treatment of overactive bladder syndrome developed by Pfizer, which was approved by the US FDA in October 2008. Fesoterodine fumarate is a prodrug, which is rapidly hydrolyzed in blood after oral administration to 5-hydroxymethyl tolterodine (5-HMT), which is also the active metabolite of tolterodine.
-
Uses
Fesoterodine fumarate (Toviaz) is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist. Fesoterodine fumarate (Toviaz) is used to treat the symptoms of overactiv (R)-Fesoterodine Fumarate is a muscarinic receptor antagonist for the treatment of Lower Urininary Tract Symptoms (LUTS). It is very similar to Tolterodine (T535800).
-
Clinical Use
Antimuscarinic:Symptomatic treatment of urinary incontinence,
frequency or urgency
-
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of antimuscarinic
side effects with disopyramide.
Antifungals: dose reduction advised with
itraconazole and ketoconazole.
Antivirals: dose reduction advised with atazanavir,
indinavir, ritonavir and saquinavir.
Induction of CYP3A4 may lead to subtherapeutic
plasma levels. Concomitant use with CYP3A4
inducers (e.g. carbamazepine, rifampicin,
phenobarbital, phenytoin, St John's Wort) is not
recommended.
Co-administration of a potent CYP2D6 inhibitor
may result in increased exposure and adverse events.
A dose reduction to 4 mg may be needed'
See 'Other information'
